Humacyte (HUMA) to Release Quarterly Earnings on Friday

Humacyte (NASDAQ:HUMA - Get Free Report) is scheduled to release its earnings data before the market opens on Friday, May 10th. Analysts expect Humacyte to post earnings of ($0.23) per share for the quarter. Persons interested in registering for the company's earnings conference call can do so using this link.

Humacyte (NASDAQ:HUMA - Get Free Report) last released its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same period in the previous year, the business posted ($0.21) EPS. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Price Performance

Shares of Humacyte stock traded up $0.07 on Tuesday, hitting $4.61. The company's stock had a trading volume of 1,163,778 shares, compared to its average volume of 1,125,693. The company has a debt-to-equity ratio of 1.20, a quick ratio of 4.52 and a current ratio of 4.52. Humacyte has a 1 year low of $1.96 and a 1 year high of $5.60. The firm has a fifty day moving average price of $3.48 and a 200-day moving average price of $3.09. The company has a market capitalization of $548.96 million, a price-to-earnings ratio of -4.42 and a beta of 1.27.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Benchmark reiterated a "buy" rating and issued a $15.00 price objective on shares of Humacyte in a report on Monday, March 25th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price objective on shares of Humacyte in a report on Monday, April 1st. Finally, Piper Sandler reiterated a "neutral" rating and issued a $4.00 price objective on shares of Humacyte in a report on Tuesday, March 26th.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.